Table 2.
Clinicopathologic characteristics of the study patients
| Characteristic | (n = 96) n (%) |
|---|---|
| Age at inclusion (years) | |
| Median | 68 |
| IQR | 61–71 |
| Male sex | 77 (80) |
| Tumor type | |
| Squamous cell carcinoma | 18 (19) |
| Adenocarcinoma | 78 (81) |
| Clinical T stagea | |
| cT1 | 1 (1) |
| cT2 | 15 (16) |
| cT3 | 77 (80) |
| cT4 | 3 (3) |
| Clinical N stageb | |
| cN0 | 33 (34) |
| cN1 | 38 (4) |
| cN2 | 19 (20) |
| cN3 | 6 (6) |
| ASA classificationc | |
| 1 | 15 (16) |
| 2 | 65 (68) |
| 3 | 14 (15) |
| Missing | 2 (2) |
IQR interquartile range, ASA American Society of Anesthesiology
aClinical tumor (cT) stage was assessed via endoscopic ultrasonography or computed tomography (CT) and classified according to the International Union for Cancer Control (IUCC) tumor-node-metastasis (TNM) classification, 7th ed
bClinical lymph-node (N) stage was assessed via endoscopic ultrasonography, CT, or 18F-fluorodeoxyglucose positron-emission tomography and classified according to IUCC TNM classification, 7th ed
cASA classification is on a scale of 0 to 5, with lower numbers indicating better physical status, 1 indicating a normal healthy patient, 2 indicating a patient with mild systemic disease, and 3 indicating a patient with severe systemic disease